Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vitamin D and Residual Beta-Cell Function in Type 1 Diabetes
NCT03046927Phase 3Completed
- Start
- Oct 2017
- Primary completion
- Apr 2021
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 1 diabetes mellitus (T1D) comparing Ergocalciferol with Placebo (2 arms). Primary endpoint: Residual Beta-cell Function (RBCF) at 12 months. Started Oct 2017; status: completed.
02
Drugs
vitamin d
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03046927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03046927.